A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial) Keywords. Pevonedistat enhanced the activity of cytarabine, cisplatin, doxorubicin, and etoposide in ABC-, but not in the GCB-DLBCL cell lines. MLN4924 is a small molecule inhibitor of Nedd8 activating enzyme ( NAE) with IC50 of 4 nM. However, the future for MDS patients is promising. LARVOL VERI predictive biomarker evidence, pevonedistat (MLN4924) Content on this site is for research purposes only and is not intended to be a substitute for medical advice. Venetoclax (Venclexta), which inhibits the activity of a protein called BCL-2; Gemtuzumab ozogamicin (Mylotarg) ... One promising drug, called pevonedistat, targets a protein called NAE that is involved in cell division and is being studied in clinical trials. Blood 130(1):2540, 2017. e-Pub 2017. ; Ades L, Watts JM, Radinoff A, et al. Preclinical studies also suggest that pevonedistat may synergize with venetoclax through neutralization of Mcl-1. Treatment. Eventually, [venetoclax] might be used in patients with t11;14, but those studies are being done. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. … Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Pevonedistat is a pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine which is substituted by a (1S)-2,3-dihydro-1H-inden-1-ylnitrilo group at position 4 and by a (1S,3S,4S)-3-hydroxy-4-[(sulfamoyloxy)methyl]cyclopentyl group at position 7. Once the study team decides that an individual is eligible to take part in the study, they will enter the treatment period. About the Pevonedistat-2001 Trial Pevonedistat-2001 (NCT02610777) is a global, randomized, controlled, open-label, multi-center, Phase 2 clinical trial designed to evaluate the safety … Washington University School of Medicine – Polycythemia vera Novartis Pharmaceuticals – Polycythemia vera . Pevonedistat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Online ahead of print. Pevonedistat is currently being evaluated in Phase 3 studies as a first-line treatment for patients with HR-MDS, HR-CMML and AML, who are ineligible (unfit) for transplant or intensive induction chemotherapy, and in a Phase 2 study in unfit AML in a triple combination with azacitidine and venetoclax. Pat, you kindly responded to my post on using venetoclax with vidaza for MDS. A mechanism-based inhibitor of NAE, and creates a covalent NEDD8-MLN4924 adduct catalyzed … Published data supporting the FDA approval of venetoclax in combination with azacitidine, decitabine or low-dose cytarabine (LDC) for patients with newly diagnosed AML aged 75 or older or those who are not candidates for intensive induction chemotherapy ... FDA breakthrough therapy designation for pevonedistat… * Drugs@FDA includes information about drugs, including biological products, approved for human use in the United States (see FAQ), but does not include information about FDA-approved products regulated by the Center for Biologics Evaluation and Research (for example, vaccines, allergenic products, blood and blood products, plasma derivatives, cellular and gene therapy products). Protocol No. Is Venetoclax an Option? The purpose of this study is to determine whether the combination of pevonedistat + venetoclax + azacitidine improves event-free survival (EFS) compared with venetoclax + azacitidine in patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. The purpose of this study is to determine whether the combination of pevonedistat + venetoclax + azacitidine improves event-free survival (EFS) compared with venetoclax + azacitidine in patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. Giving azacitidine, venetoclax, and pevonedistat may work better in treating patients with acute myeloid leukemia.. It is administered as an intravenous (IV) infusion, while azacitidine is administered as either a subcutaneous injection or an IV infusion, and venetoclax is taken as an oral tablet. How safe and effective any of these strategies are remains to be determined. In recent years, we are witnessing the emergence of multiple treatment combinations based on hypomethylating agents (pevonedistat, magrolimab, eprenetapopt, venetoclax) that have proven to be effective in MDS, even those with high-risk factors. Pevonedistat is currently being evaluated in Phase 3 studies as a first-line treatment for patients with HR-MDS, HR-CMML and AML, who are ineligible (unfit) for transplant or intensive induction chemotherapy, and in a Phase 2 study in unfit AML in a triple combination with azacitidine and venetoclax. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. It also exhibited synergy with ibrutinib, selinexor, venetoclax and A-1331852 (a novel BCL-XL inhibitor). 1 Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia Authors: Dan Cojocari1*, Brianna N Smith2-4*, Julie J Purkal1, Maria P Arrate3, Jason D Huska1, Yu Xiao1, Agnieszka Gorska3, Leah J Hogdal5, Haley E. Ramsey3,4, Erwin R Boghaert1, Darren C Phillips1**, Michael R Savona3,4,6,7**†. European Medicines Agency - For help on how to get the results you want, see our search tips. Both pevonedistat and Ven, a BCL-2 inhibitor, have been shown to improve survival when combined with aza, compared to aza alone. 2021 Apr 15. doi: 10.3324/haematol.2020.272609. You said you heard venetoclax was going to be approved for MDS in August. Phase III_GDC-9545 RO7197597_Breast Cancer_Roche BO41843 A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined With … Clinical Trials Search at Vanderbilt-Ingram Cancer Center. Link to Tulane Home Page. A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy. ; Ades L, Watts JM, Radinoff A, et al. The study will enroll approximately 150 patients. Pevonedistat is currently being evaluated in Phase 3 studies as a first-line treatment for patients with HR-MDS, HR-CMML and AML, who are ineligible (unfit) for transplant or intensive induction chemotherapy, and in a Phase 2 study in unfit AML in a triple combination with azacitidine and venetoclax. The purpose of this study is to determine whether the combination of pevonedistat + venetoclax … Triple Combination of Pevonedistat and Venetoclax Plus Azacitidine in Adults With Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy. Pevonedistat is the first small-molecule inhibitor of the neural precursor cell expressed, developmentally downregulated 8 (NEDD8)-activating enzyme (NAE); … By … These agents added to the HMA/venetoclax doublet include: a combination of cladribine and low-dose cytarabine, the NEDD8-actviating enzyme inhibitor pevonedistat, the anti-CD33 antibody/calicheamicin conjugate gemtuzumab ozogamicin, MDM2 inhibitors, and the anti-programmed death ligand-1 (PDL-1) antibody avelumab . This treatment has shown impressive response rates in elderly patients with AML. In recent years, we are witnessing the emergence of multiple treatment combinations based on hypomethylating agents (pevonedistat, magrolimab, eprenetapopt, venetoclax… • Patient with known hypersensitivity to pevonedistat, venetoclax, or azacitidine, and/or their excipients. The study hypothesis is that the combination of pevonedistat, azacitidine, and venetoclax will be effective, safe, and well tolerated in patients with AML.The primary objective of this portion of the study is to determine a recommended phase 2 dose (RP2D) of pevonedistat, azacitidine, and venetoclax… Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for its … nations based on hypomethylating agents (pevonedistat, magrolimab, eprenetapopt, venetoclax) that have proven to be effective in MDS, even those with high-risk factors. Participants in Arm A will receive the study drug pevonedistat in combination with venetoclax … What about you Uwe, like globally, if you look at your crystal ball and over the next five years, let’s say for the MDS field, we have three different or at least actually five phase three trials that are ongoing with pevonedistat, magrolimab, APR-246, sabatolimab and venetoclax … J Immunother Cancer. Patients receive venetoclax orally (PO) once daily (QD) on days 1-28, azacitidine intravenously (IV) or subcutaneously (SC) on days 1-7, and pevonedistat IV over 60 minutes on days 1, 3, and 5. enzyme (NAE) inhibitors (e.g., pevonedistat) and the mouse double minute 2 homolog protein (MDM2) inhibitor KRT-232, being added to the HMA/venetoclax backbone, understanding the mechanisms of … • Patient is known to be positive for hepatitis B or C infection, with the … 2020;8:e000911. The drug being tested in this study is called Pevonedistat. Aims To determine the dose-limiting toxicities (DLTs) of the combination of azacitidine, venetoclax, and pevonedistat in patients (pts) with previously untreated s-AML and to preliminarily assess efficacy of the regimen. Overall, the safety profile of pevonedistat + azacitidine was comparable to that of azacitidine alone (Table 1 ). Grade ≥ 3 TEAEs were reported in 90% of patients with pevonedistat + azacitidine versus 87% with azacitidine. Pevonedistat inhibits proteasomal degradation of intracellular proteins by inhibiting neural precursor cell expressed, developmentally downregulated 8 (NEDD8)-activating enzyme and has been demonstrated to have synergistic effects with AZA and venetoclax in preclinical models of AML [61, 62]. Pevonedistat-2002 A Randomized, Open-Label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid … Participants will be chosen at random to be in one of two treatment arms: Arm A or Arm B. Cell Death Differ. Should We Consider Magrolimab? The combination of pevonedistat and azacitidine had encouraging clinical activity in patients with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia … • Patient is known to be positive for hepatitis B or C infection, with the exception of those with an undetectable viral load within 3 months. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy characterized by aberrant proliferation of immature thymocytes. In addition, pevonedistat is being evaluated in a phase 2 study in combination with azacitidine and venetoclax … Pevonedistat is being tested to treat people who have AML. Learn more about: Polycythemia vera . The purpose of this study is to determine whether the combination of pevonedistat + venetoclax … Pevonedistat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Pevonedistat is a selective NEDD8 inhibitor that interferes with proteasome-mediated protein degradation and DNA repair, thereby causing apoptosis in malignant cells. Acute Myeloid Leukemia Leukemia Azacitidine Pevonedistat Venetoclax Pevonedistat inhibits NEDD8-activating enzyme (NAE), causing cell cycle disturbance and cell death in cancers. Pevonedistat is an inhibitor of the NEDD8-activating enzyme and is being developed for the treatment of malignancies. A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy. Participants will be chosen at random to be in one of two treatment arms: Arm A or Arm B. Tim-3 finds its place in the cancer immunotherapy landscape. Alvocidib Enhances Venetoclax Sensitivity in Unfavorable-Risk Multiple Myeloma Cells In Vitro and In Vivo. However, the future for MDS patients is promising. Pevonedistat treatment disrupts cell cycle progression and cell survival, leading to cell death in cancers including leukemias. Once the study team decides that an individual is eligible to take part in the study, they will enter the treatment period. Triple Combination of Pevonedistat and Venetoclax Plus Azacitidine in Adults With Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy. The study will enroll approximately 150 patients. Pevonedistat is currently being evaluated in Phase 3 studies as a first-line treatment for patients with HR-MDS, HR-CMML and AML, who are ineligible (unfit) for transplant or intensive induction chemotherapy, and in a Phase 2 study in unfit AML in a triple combination with azacitidine and venetoclax. 17 Professor DiNardo finished with data demonstrating improved survival outcomes for patients with NPM1 mutated AML treated with an HMA plus venetoclax … Venetoclax was initially given at a dose of 400 mg or 800 mg for 28 days in a 28-day treatment cycle. This first-in-class NEDD8-activating enzyme inhibitor was shown to be more effective when combined with azacitidine than when azacitidine was administered alone. Methods Pevonedistat is an NEDD8-activating enzyme (NAE) inhibitor administered via intravenous infusion. Arm A: Pevonedistat + Venetoclax + Azacitidine: Pevonedistat 20 mg/m^2 as a 60-minute intravenous (IV) infusion on Days 1, 3, and 5 in each 28-day cycle plus venetoclax 100 mg tablet orally on Day 1; 200 mg on Day 2; thereafter, at 400 mg on Day 3 through Day 28 in Cycle 1 and 400 mg on Days 1 through 28 in Cycle 2 and beyond if tolerated. Filter By: Clear Filters Benign Hematologic; Bladder; Breast; Cervical; Colon; Dermatologic Even with current treatment options, outcomes for people living with HR-MDS remain poor. MLN4924 is a small molecule inhibitor of Nedd8 activating enzyme ( NAE) with IC50 of 4 nM. A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are … In vivo, the combination of pevonedistat open to eligible people ages 18 years and up . Pevonedistat … Pevonedistat is currently being evaluated in Phase 3 studies as a first-line treatment for patients with HR-MDS, HR-CMML and AML, who are ineligible (unfit) for transplant or intensive induction chemotherapy, and in a Phase 2 study in unfit AML in a triple combination with azacitidine and venetoclax. This study will compare the improvement in EFS in Arm A: pevonedistat + venetoclax + azacitidine combination arm group when compared with Arm B: venetoclax + azacitidine. The clinical research supply of the CTEP agents, below, is largely for the National Clinical Trials Network () and the Experimental Therapeutics Clinical Trials Network (), however investigators from certain NCI-designated Cancer Centers not affiliated with these networks may … Learn more about how it's being used in clinical trials in this important Myeloma … AML 40: A Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination with Azacitidine in Patients with Acute Myeloid Leukemia.PI: Suman Kambhampati, MD Facility: Research Medical Center. Despite an overall survival of 80% in the pediatric setting, 20% of patients with T-ALL ultimately die from relapsed or refractory disease. About this study The purpose of this study is to determine a recommended phase 2 dose (RP2D) of pevonedistat, azacitidine, and venetoclax to treat Acute Myelogenous Leukemia. About MDS MDS is a rare form of bone marrow-related cancer caused by irregular blood … Pevonedistat enhanced the activity of cytarabine, cisplatin, doxorubicin and etoposide in ABC-, but not in the GCB-DLBCL cell lines. It is also being evaluated in a Phase 2 study in unfit AML in a triple combination with azacitidine and venetoclax. Participants in Arm A will receive the study drug pevonedistat in combination with venetoclax … Previously Untreated Acute Myeloid Leukemia Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Cytarabine Azacitidine Decitabine Daunorubicin Venetoclax AZD5991 Pevonedistat … AbbiVie M19-072. Pevonedistat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Details. Phase II study of pevonedistat … Giving azacitidine, venetoclax, and pevonedistat may work better in treating patients with acute myeloid leukemia. TAKEDA-TAK-P2002-AML. J Immunother Cancer. Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem-cell disorders that result in cytopenias and the risk of progression to acute myeloid leukemia (AML).Although there … 2020;8:e000911. Acharya N, Sabatos-Peyton C, Anderson AC. PRE0905. Inhibiting NAE blocks ubiquitination of select proteins upstream of the proteasome. The study will enroll approximately 150 patients. Tim-3 finds its place in the cancer immunotherapy landscape. Therefore, there is an urgent need for novel therapies. • Uncontrolled HIV infection. Official Title. A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are … open to eligible people ages 18 years and up . The trial testing the combination of venetoclax with AZA in patients with HR-MDS, including HMA failure, is currently recruiting (NCT02966782). Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia. Pevonedistat is an investigational drug for which safety and efficacy have not been established. May 27, 2020 checkorphan. A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax … A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy. B-cell lymphoma protein-2 (BCL2) overexpression is a common feature in hematologic malignancies. At present, pevonedistat is being assessed in phase 3 studies as a first-line treatment for patients with HR-MDS, HR-CMML and AML, who are ineligible for transplant or intensive induction chemotherapy. NCT04266795. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Preclinical studies evaluating the combination of pevonedistat and venetoclax against AML cell lines have demonstrated synergistic effect (Knoor KL et al. Pevonedistat + AZA vs. AZA alone: II: NCT03238248: HMA-refractory MDS or MDS/MPN: Pevonedistat + AZA: Venetoclax (BCL2 inhibitor) II: NCT04146038: R/R-AML or MDS: Salsalate + DEC/AZA + venetoclax… Giving azacitidine, venetoclax, and pevonedistat may work better in treating patients with acute myeloid leukemia. Randomized Trial of Gilteritinib vs … • Uncontrolled HIV infection. Penn Update on Novel Therapies for Higher Risk MDS: What Is the Role of Pevonedistat & Sabatolimab? AML 52: Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine VS Venetoclax … This study will compare the improvement in EFS in Arm A: pevonedistat + venetoclax + azacitidine combination arm group when compared with Arm B: venetoclax + azacitidine. Pevonedistat … It also exhibited synergy with ibrutinib, selinexor, venetoclax, and A-1331852 (a novel BCL-XL inhibitor). Phase II study of pevonedistat (P) + azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low-blast acute … Pevonedistat + AZA vs. AZA alone: II: NCT03238248: HMA-refractory MDS or MDS/MPN: Pevonedistat + AZA: Venetoclax (BCL2 inhibitor) II: NCT04146038: R/R-AML or MDS: Salsalate + DEC/AZA + venetoclax: I/II Pevonedistat is being tested to treat people who have AML. Pevonedistat for MDS Medical professionals are very excited by the results they have seen in trials of pevonedistat plus azacitidine. Principal Investigator. Pevonedistat is a first in class NEDD8-activating enzyme (NAE) inhibitor, which blocks modifications of select proteins. Pevonedistat … Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia who are Unfit for Intensive Chemotherapy nedd8 activating … Dysregulation of apoptotic machinery is one mechanism by which acute myeloid leukemia (AML) acquires a clonal survival advantage. Pevonedistat is being tested to treat people who have AML. Pevonedistat-2002 A Randomized, Open-Label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy More Information . The press release notes that pevonedistat could offer a new option for patients with higher … Is Enasidenib Effective in IDH2 MDS? Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax … Venetoclax, Selinexor, A-1331852, and Ibrutinib were obtained by Selleck Chemicals (Houston, TX). List of Agents Available Under CTEP Collaborative Agreements for Clinical and Non-clinical Studies Clinical Use. expression of BCL-2/Bcl-XL, and upregulation of BAK levels. In this group of patients, both EFS and OS favored pevonedistat … Acharya N, Sabatos-Peyton C, Anderson AC. Furthermore, the approval in the US of an oral hypomethylating agent opens the door to … Triple Combination of Pevonedistat and Venetoclax Plus Azacitidine in Adults With Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy (PEVENAZA) Pevonedistat is a compound that inhibits neddylation that has been studied in multiple trials encompassing both MDS and AML. A mechanism-based inhibitor of NAE, and creates a covalent NEDD8-MLN4924 adduct catalyzed by the enzyme. The selective BCL2 inhibitor, venetoclax (VEN) is used in combination with azacitidine (AZA), a DNA-methyltransferase inhibitor (DNMTi), to treat patients with … 2015). This study will compare the improvement in EFS in Arm A: pevonedistat + venetoclax + azacitidine combination arm group when compared with Arm B: venetoclax + azacitidine. Everyone in this study will receive pevonedistat, azacitidine and venetoclax. Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia Haematologica. 2020-0301 - A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid … Could you tell me where you got … Approval for that is a long way down the road. Pevonedistat is currently being evaluated in Phase 3 studies as a first-line treatment for patients with HR-MDS, HR-CMML and AML, who are ineligible (unfit) for transplant or intensive induction chemotherapy, and in a Phase 2 study in unfit AML in a triple combination with azacitidine and venetoclax. The drug being tested in this study is called Pevonedistat. Also, in unfit patients, different combination partners for venetoclax, e.g., pevonedistat… Pevonedistat, a first in class NEDD8-activating enzyme (NAE) inhibitor, could be the first novel treatment for HR-MDS patients in more than a decade, expanding treatment options that have so far been limited to hypomethylating agent (HMA) monotherapy alone. Pevonedistat was provided by Millennium Pharmaceuticals, Inc. (Cambridge, MA), a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Pevonedistat … Background:Outcomes of patients with AML have remained poor despite the availability of cytotoxic chemotherapy, hypomethylating agents (HMAs) and targ… TMD8 and U2932 represented the ABC‐DLBCL subtype; OCI‐LY2 and SUDHL4 represented the GCB‐DLBCL subtype. Cell cycle and apoptosis threshold changes following NAE inhibition were evaluated. DLBCL cell lines were exposed in vitro to pevonedistat (25‐125 nM) for 48 h. MLN4924 is structurally related to adenosine 59-monophosphate (AMP)—a tight binding product of the NAE reaction. The drug being tested in this study is called Pevonedistat. Description The study hypothesis is that the combination of pevonedistat, azacitidine, and venetoclax will be effective, safe, and well tolerated in patients with AML. Pevonedistat is currently being evaluated in Phase 3 studies as a first-line treatment for patients with HR-MDS, HR-CMML and AML, who are ineligible (unfit) for transplant or intensive induction chemotherapy, and in a Phase 2 study in unfit AML in a triple combination with azacitidine and venetoclax. Venetoclax could be considered the first and true "personalized medicine" for multiple myeloma patients. Pevonedistat-2002 A Randomized, Open-Label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy. The “hypomethylating agents” (HMAs) azacitidine (5-azacitidine) and decitabine (5-aza-2ʹ-deoxycytidine) are nucleoside derivatives that are incorporated into DNA, where they inhibit DNA methyltransferases (DNMT). One of the most promising combinations was shown the Blast MRD AML-2 study, where venetoclax was combined with azacytidine and pembrolizumab a PD-1 inhibitor . Pevonedistat-2002 A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid … These agents added to the HMA/venetoclax doublet include: a combination of cladribine and low-dose cytarabine, the NEDD8-actviating enzyme inhibitor pevonedistat, the anti-CD33 antibody/calicheamicin … Currently, pevonedistat is being evaluated in a phase 3 study for first-line treatment of HR-MDS, HR-CMML and AML patients who are not eligible for transplantation or intensive induction chemotherapy. Related Access Program. Leukemia. 988 A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive … • Patient with known hypersensitivity to pevonedistat, venetoclax, or azacitidine, and/or their excipients. Triple Combination of Pevonedistat and Venetoclax Plus Azacitidine in Adults With Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy. Pevonedistat is the first small-molecule inhibitor of neural precursor cell expressed, developmentally downregulated protein 8 (NEDD8)-activating enzyme (NAE). 24,25 Study P-2001 enrolled patients with higher-risk MDS, AML, or CMML; this analysis was restricted to the 67 patients with higher-risk MDS. Treatment.